NASDAQ$SKIN
SkinHealth Systems Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Net sales beat expectations for the seventh consecutive quarter and the company raised 2022 net sales guidance.
BeautyHealth reported strong Q3 2022 financial results, with net sales of $88.8 million, representing a 30% year-over-year growth. The company raised its full year net sales guidance to $360 million to $365 million. Adjusted EBITDA for the quarter was $16.5 million, with a GAAP net income of $0.1 million. However, due to increasing macro pressures, the company revised its full year 2022 adjusted EBITDA guidance to a range of $45.0 to $50.0 million.
- Net sales increased by 30% year-over-year to $88.8 million.
- Gross margin improved by 174bps year-over-year to 69.3%.
- Net income was $0.1 million, compared to a net loss of $215.1 million in Q3 2021.
- Adjusted EBITDA was $16.5 million.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$88.8M
Revenue by segment
Beauty Health · $88.8M total across 2 segments · Q3 2022
- Delivery Systems$49.1M+35.6%55.3%
- Consumables$39.7M+24.1%44.7%
Forward guidance
BeautyHealth increased its fiscal 2022 net sales guidance and now expects net sales in the range of $360.0 million to $365.0 million. The Company also expanded its 2022 outlook for adjusted EBITDA from the prior target of $50.0 million to a range of $45.0 million to $50.0 million.
Tailwinds
- Net sales guidance increased to $360 million - $365 million.
- Reflects management's confidence in the business.
- Company executes against its growth plan.
Headwinds
- Adjusted EBITDA outlook revised to $45 million - $50 million.
- Continued investment in global expansion.
- Changing macroeconomic pressures.
- Foreign currency exchange headwinds.
- Market closures and restrictions as a result of China’s zero COVID policy.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro